Source-grounded facts extracted from LIGAND PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LIGAND PHARMACEUTICALS INC amended Fourth Amendment with Citibank, N.A., as Administrative Agent (effective 2026-06-22).
“on June 22, 2026, Ligand Pharmaceuticals Incorporated (the “Company”), as borrower, entered into a Consent and Fourth Amendment to Credit Agreement (the “Fourth Amendment”) with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N.A., as Administrative Agent (as defined therein)”
LIGAND PHARMACEUTICALS INC shareholders approved Approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan.
“Proposal 4. The approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan. In accordance with the results below, the proposal was approved.”
LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers.
“Proposal 3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers. In accordance with the results below, the proposal was approved.”
LIGAND PHARMACEUTICALS INC shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. In accordance with the results below, the selection of Ernst & Young LLP was ratified.”
LIGAND PHARMACEUTICALS INC shareholders approved Election of eight members of the Board of Directors for terms expiring at the 2027 annual meeting.
“Proposal 1. The election of eight members of the Board of Directors of the Company for terms expiring at the 2027 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director of the Company.”
LIGAND PHARMACEUTICALS INC amended Amendment No. 1 to the Agreement and Plan of Merger with XOMA Royalty Corporation (effective 2026-05-16).
“On May 16, 2026, XOMA Royalty, Ligand and the Merger Sub entered into Amendment No. 1 to the Agreement and Plan of Merger”
LIGAND PHARMACEUTICALS INC entered into Agreement and Plan of Merger with XOMA Royalty Corporation (effective 2026-04-27).
“As previously disclosed, on April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“ XOMA Royalty ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand (“ Merger Sub ”), pursuant to which, and upon the terms and subject to the conditions thereof, including, without limitation, effecting the Holding Company Reorganization (as defined below), Merger Sub will merge with and into a newly formed Nevada corporation, XOMA Royalty Holdings Corporation (“ HoldCo ”), (the “ Merger ”), with HoldCo surviving the Merger as a wholly owned subsidiary of Ligand.”
LIGAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $51.7 million, net income GAAP net loss was $13.3 million, or $0.67 per share, EPS $0.67 per share. Guidance reaffirmed.
“results reflect continued strong momentum in the royalty business, with royalty revenue growing 56% year-over-year. Total revenues and income for the first quarter of 2026 were $51.7 million, compared with $45.3 million for the same period in 2025, with the 14% increase primarily driven by higher royalty revenue. Royalties for the first quarter of 2026 were $43.0”
LIGAND PHARMACEUTICALS INC terminated Master License Agreement with Viking Therapeutics, Inc. (effective 2026-04-24).
“On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).”
LIGAND PHARMACEUTICALS INC entered into Agreement and Plan of Merger with XOMA Royalty Corporation (effective 2026-04-27).
“On April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“ XOMA Royalty ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand (“ Merger Sub ”)”
LIGAND PHARMACEUTICALS INC amended credit facility with Citibank, N.A. maturing September 12, 2028.
“to, among other things, extend the maturity date to September 12, 2028 and modify the minimum consolidated EBITDA”
LIGAND PHARMACEUTICALS INC incurred convertible notes of $460,000,000 with U.S. Bank Trust Company, National Association at 0.75% per year maturing October 1, 2030.
“On August 14, 2025, Ligand Pharmaceuticals Incorporated (the “ Company ”) completed its previously announced private offering of $460.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the “ Notes ”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $60.0 million aggregate principal amount of Notes. The Notes were issued pursuant to an indenture, dated August 14, 2025 (the “ Indenture ”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”
Matthew Korenberg departed as President and Chief Operating Officer at LIGAND PHARMACEUTICALS INC.
“On August 2, 2024, Ligand Pharmaceuticals Incorporated (the “Company”) announced that its President and Chief Operating Officer, Matthew Korenberg, will be departing from the Company.”
LIGAND PHARMACEUTICALS INC completed an acquisition involving APEIRON Biologics AG for $100 million in cash at closing (closed 2024-07-15).
“On July 15, 2024, Ligand completed the acquisition of APEIRON pursuant to the terms of the Agreement for an aggregate amount of $100 million.”
LIGAND PHARMACEUTICALS INC reported 2024 results: revenue $130 million to $142 million, EPS approximately $4.25 to $4.75. Guidance reaffirmed.
“Ligand is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million. Ligand notes that with total revenue of $130 million to $142 million, core adjusted earnings per diluted share are expected to range from approximately $4.25 to $4.75.”
LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $31.0 million, net income $86.1 million, EPS $4.75 per diluted share.
“Total revenues and other income for the first quarter of 2024 were $31.0 million, compared with $44.0 million for the same period in 2023. Royalties for the first quarter of 2024 were $19.1 million, compared with $17.6 million for the same period in 2023, with the increase primarily attributable to Amgen’s (Nasdaq: AMGN) Kyprolis, Jazz Pharmaceuticals' (Nasdaq: JAZZ) RYLAZE, Merck and Co.’s (NYSE: MRK) VAXNEUVANCE and Travere Therapeutics’ (Nasdaq: TVTX) FILSPARI, partially offset by a decline in CASI’s (Nasdaq: CASI) EVOMELA. Captisol sales were $9.2 million for the first quarter of 2024, compared with $10.6 million for the same period in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024, compared with $15.7 million for the same period in 2023, with the difference driven by a $15.3 million milestone payment earned from Travere Therapeutics upon the FDA approval of FILSPARI in the prior year quar”
LIGAND PHARMACEUTICALS INC entered into Purchase and Sale Agreement, dated May 6, 2024 (the "Agreement") with Agenus Inc., Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC (collectively, "Sellers") valued at $75 million (effective 2024-05-06).
“On May 6, 2024, Ligand Pharmaceuticals Incorporated (“Ligand”) entered into that certain Purchase and Sale Agreement, dated May 6, 2024 (the “Agreement”), with Agenus Inc., Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC (collectively, “Sellers”), where Ligand will obtain certain royalty rights for an aggregate purchase price of $75 million.”
LIGAND PHARMACEUTICALS INC: Adopted Fifth Amended and Restated Bylaws with updates for universal proxy rules, DGCL amendments, and other revisions (effective 2024-04-17).
“On April 17, 2024, the Board of Directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”), in connection with the Securities and Exchange Commission’s revisions to the Securities Exchange Act of 1934, as amended (the "Exchange Act") regarding universal proxy cards, changes to the Delaware General Corporation Law (the "DGCL"), and a periodic review of corporate governance matters, approved the amendment and restatement of the Company’s Fourth Amended and Restated Bylaws, as amended (the “Fifth Amended and Restated Bylaws”).”
LIGAND PHARMACEUTICALS INC reported financial results for the three and twelve months ended December 31, 2023.
“On February 27, 2024, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.”
LIGAND PHARMACEUTICALS INC amended Amendment No. 2 to Development Funding and Royalties Agreement with Palvella Therapeutics, Inc. valued at upfront payment of $5 million; increased tiered royalty between 8.0% and 9.8% based on annual aggreg (effective 2023-11-29).
“According to the terms of the Amendment No. 2 to Development Funding and Royalties Agreement, dated as of November 29, 2023 (the "Amendment"), between Ligand and Palvella, Palvella received an upfront payment of $5 million from Ligand.”
LIGAND PHARMACEUTICALS INC reported three and nine months ended September 30, 2023 results: revenue $32.9 million, net income $10.3 million net loss, EPS $0.59 per share loss. Guidance raised.
“at our upcoming Investor and Analyst Day scheduled for December 12th in New York City.” Third Quarter 2023 Financial Results Total revenues for the third quarter of 2023 were $32.9 million. Revenues for the same period in 2022 excluding sales related to COVID-19 were $26.9 million. Total revenues for the third quarter of 2022 including COVID-19 related sales were”
LIGAND PHARMACEUTICALS INC updated its three and nine months ended September 30, 2023 guidance (raised).
“On November 8, 2023, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.”
LIGAND PHARMACEUTICALS INC entered into Credit Agreement with Citibank, N.A. as the Administrative Agent valued at $75 million (effective 2023-10-12).
“On October 12, 2023, Ligand Pharmaceuticals Incorporated (the “Company”), entered into a $75 million revolving credit facility with Citibank, N.A. as the Administrative Agent.”
Martine Zimmermann was appointed as member of Board at LIGAND PHARMACEUTICALS INC.
“On September 22, 2023, the board of directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Martine Zimmermann as a member of Board.”
LIGAND PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue Total revenues for the six months ended June 30, 2023 were $70.3 million., net income Net income from continuing operations for the six months ended June 30, 2023 was $45.9 million, or $2.57 per diluted sha, EPS $2.57 per diluted share. Guidance reaffirmed.
“Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
LIGAND PHARMACEUTICALS INC reported the three and six months ended June 30, 2023 results: revenue Total revenues for the second quarter of 2023 were $26.4 million., net income Net income from continuing operations for the second quarter of 2023 was $2.3 million, or $0.13 per diluted share, EPS $0.13 per diluted share. Guidance reaffirmed.
“Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the frequency of the advisory vote on the compensation of the Company's named executive officers at the 2023-06-09 meeting.
“Proposal 4 . The approval of a non-binding advisory resolution regarding the frequency of the advisory vote on the compensation of the Company’s named executive officers. Based on the results below, the Company has determined that it will hold a stockholder advisory vote on the compensation of the Company’s named executive officers every year. 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 13,490,718 29,347 567,460 12,055 1,765,888”
LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers at the 2023-06-09 meeting.
“Proposal 3 . The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers. In accordance with the results below, the resolution was approved. Votes For Votes Against Abstentions Broker Non-Votes 12,379,762 1,698,528 21,290 1,765,888”
LIGAND PHARMACEUTICALS INC shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-09 meeting.
“Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. In accordance with the results below, the selection of Ernst & Young LLP was ratified. Votes For Votes Against Abstentions Broker Non-Votes 15,512,124 347,261 6,083 N/A”
LIGAND PHARMACEUTICALS INC shareholders approved Election of seven members of the Board of Directors for terms expiring at the 2024 annual meeting at the 2023-06-09 meeting.
“Proposal 1. The election of seven members of the Board of Directors of the Company for terms expiring at the 2024 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director. Votes For Votes Withheld Broker Non-Votes Jason M. Aryeh 7,967,581 6,131,999 1,765,888 Todd C. Davis 13,729,132 370,448 1,765,888 Nancy R. Gray, Ph.D. 13,426,347 673,233 1,765,888 Jason Haas 13,450,640 648,940 1,765,888 John W. Kozarich, Ph.D. 9,920,043 4,179,537 1,765,888 John L. LaMattina, Ph.D. 13,372,521 727,059 1,765,888 Stephen L. Sabba, M.D. 13,313,876 785,704 1,765,888”
LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2023 results: revenue $44.0 million, net income $43.6 million, or $2.43 per diluted share. Guidance raised.
“Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. “2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said”
LIGAND PHARMACEUTICALS INC reported 2022 results: revenue $196.2 million, net income $5.2 million net loss, EPS $0.31 per share. Guidance raised.
“Total revenues for 2022 were $196.2 million, compared with $241.5 million for 2021. Royalties for 2022 were $72.5 million, compared with $48.9 million for 2021, with the increase primarily attributable to the growth in sales of drugs using the Pelican platform. Core Captisol sales were $16.4 million for 2022, compared with $23.4 million for 2021. The difference in sales was due to the timing of customer orders. Captisol sales related to COVID-19 were $88.1 million for 2022, compared with $140.8 million for 2021. The lower sales are due to reduced demand for the pandemic-related treatment. Contract revenue for 2022 was $19.2 million, compared with $28.4 million for 2021, with the change due to the timing of partner milestone events. Cost of Captisol was $52.8 million for 2022, compared with $62.2 million for 2021, with the decrease due primarily to lower sales of Captisol, partially offset by $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the year. A”
LIGAND PHARMACEUTICALS INC reported the fourth quarter of 2022 results: revenue $50.4 million, net income $14.5 million net loss, EPS $0.86 per share. Guidance raised.
“Total revenues for the fourth quarter of 2022 were $50.4 million, compared with $56.4 million for the same period in 2021. Royalties for the fourth quarter of 2022 were $22.0 million, compared with $17.6 million for the same period in 2021, with the increase primarily attributable to the growth in sales of drugs using the Pelican platform. Core Captisol sales were $3.3 million for the fourth quarter of 2022, compared with $7.1 million for the same period in 2021. The difference in sales was due to the timing of customer orders. Captisol sales related to COVID-19 were $23.5 million for the fourth quarter of 2022, compared with $28.3 million for the same period in 2021. Contract revenue was $1.5 million for the fourth quarter of 2022, compared with $3.5 million for the same period in 2021. The difference was due to the timing of partner milestone events. Cost of Captisol was $21.6 million for the fourth quarter of 2022, compared with $12.0 million for the same period in 2021, with the in”
Todd C. Davis was appointed as Chief Executive Officer at LIGAND PHARMACEUTICALS INC.
“Todd C. Davis was appointed Chief Executive Officer of the Company”
John L. Higgins resigned as Member of the Board at LIGAND PHARMACEUTICALS INC.
“Mr. Higgins also resigned as a member of the Board, effective December 31, 2022.”
John L. Higgins retired as Chief Executive Officer at LIGAND PHARMACEUTICALS INC.
“John L. Higgins has retired as Chief Executive Officer of the Company”
LIGAND PHARMACEUTICALS INC updated its the three and nine months ended September 30, 2022 guidance (raised).
“On November 7, 2022, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”
LIGAND PHARMACEUTICALS INC completed a disposition involving New OmniAb, Inc. (formerly Avista Public Acquisition Corp. II) (closed 2022-11-01).
“On November 1, 2022 (the “Distribution Date”), Ligand completed the separation (the “Separation”) of its antibody discovery business and certain related assets and liabilities (the “OmniAb Business”) through a spin-off of Legacy OmniAb to Ligand’s shareholders of record as of October 26, 2022 (the “Record Date”) on a pro rata basis (the “Distribution”) and merger (the “Merger”) of Legacy OmniAb with a wholly owned subsidiary of New OmniAb in a Reverse Morris Trust transaction (collectively, the “Transactions”)”
Octavio Espinoza was appointed as Chief Financial Officer at LIGAND PHARMACEUTICALS INC.
“Octavio Espinoza , 52, was appointed as Ligand’s Chief Financial Officer, replacing Mr. Korenberg in his roles as principal financial officer and principal accounting officer.”
Matthew Korenberg was appointed as President and Chief Operating Officer at LIGAND PHARMACEUTICALS INC.
“Matthew Korenberg , 47, who until then served as Ligand’s Executive Vice President, Finance and Chief Financial Officer was appointed as Ligand’s President and Chief Operating Officer.”
Charles Berkman resigned as Senior Vice President, General Counsel and Secretary at LIGAND PHARMACEUTICALS INC.
“Matthew Foehr and Charles Berkman resigned as Ligand’s President and Chief Operating Officer and Senior Vice President, General Counsel and Secretary, respectively.”
Matthew Foehr resigned as President and Chief Operating Officer at LIGAND PHARMACEUTICALS INC.
“Matthew Foehr and Charles Berkman resigned as Ligand’s President and Chief Operating Officer and Senior Vice President, General Counsel and Secretary, respectively.”
Sunil Patel resigned as director at LIGAND PHARMACEUTICALS INC.
“Sarah Boyce, Jennifer Cochran and Sunil Patel each resigned from Ligand’s board of directors.”
Jennifer Cochran resigned as director at LIGAND PHARMACEUTICALS INC.
“Sarah Boyce, Jennifer Cochran and Sunil Patel each resigned from Ligand’s board of directors.”
Sarah Boyce resigned as director at LIGAND PHARMACEUTICALS INC.
“Sarah Boyce, Jennifer Cochran and Sunil Patel each resigned from Ligand’s board of directors.”
Jason Haas was appointed as Director at LIGAND PHARMACEUTICALS INC.
“Effective as of June 29, 2022, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jason Haas to the Company’s Board of Directors.”
Jennifer Cochran was appointed as Director at LIGAND PHARMACEUTICALS INC.
“Effective as of July 12, 2021, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jennifer Cochran, Ph.D., to the Company’s Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.